Leukaemia patient drug boost

Acute Myeloid Leukaemia patients given a new type of smart drug in addition to chemotherapy treatment are 22 percent less likely to relapse and around 13 percent less likely to die from their disease, according to a study released today.

View all 4 updates ›

Smart drug improves survival in older patients

Kate Law, Cancer Research UK's director of clinical research, added:

In general the outlook for leukaemia patients has improved dramatically in recent decades. But when leukaemia is diagnosed in older people its much harder to treat and there is a real need for effective treatments that are suitable for this age group.

Importantly this new trial shows that GO may have particular benefits for patients over 60, who may be unsuitable for other more intensive treatments. This is good news and we are now looking to see if these results can be replicated in younger patients.

More top news